Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $27.44.
Several research analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $31.00 price target on shares of Nurix Therapeutics in a report on Thursday, September 7th. HC Wainwright lifted their price target on Nurix Therapeutics from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, September 8th.
Nurix Therapeutics Stock Performance
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last announced its quarterly earnings data on Thursday, July 13th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.12. The company had revenue of $30.68 million for the quarter, compared to analyst estimates of $21.96 million. Nurix Therapeutics had a negative return on equity of 53.36% and a negative net margin of 258.37%. On average, equities analysts predict that Nurix Therapeutics will post -2.55 earnings per share for the current year.
Institutional Trading of Nurix Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Innovis Asset Management LLC purchased a new stake in Nurix Therapeutics in the 1st quarter valued at about $267,000. Swiss National Bank raised its holdings in Nurix Therapeutics by 7.8% in the 4th quarter. Swiss National Bank now owns 85,200 shares of the company’s stock valued at $935,000 after buying an additional 6,200 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Nurix Therapeutics by 21.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 29,537 shares of the company’s stock valued at $262,000 after buying an additional 5,279 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Nurix Therapeutics in the 1st quarter valued at about $116,000. Finally, B. Metzler seel. Sohn & Co. AG grew its position in Nurix Therapeutics by 35.3% in the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 17,337 shares of the company’s stock valued at $154,000 after acquiring an additional 4,526 shares in the last quarter. 90.36% of the stock is currently owned by hedge funds and other institutional investors.
About Nurix Therapeutics
Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
- Five stocks we like better than Nurix Therapeutics
- How to Invest in Insurance Companies: A Guide
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- What Are the FAANG Stocks and Are They Good Investments?
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Health Care Stocks Explained: Why You Might Want to Invest
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.